Oxford, UK - May 31, 2023 - Evariste, a leading AI-driven drug discovery company with an end-to-end platform for finding and optimizing novel candidate drugs, announced today that it has enhanced its operations by adopting CDD Vault, a cloud-based platform for managing research data and collaborations designed and developed by Collaborative Drug Discovery, Inc.
Evariste is a research and development company with a mission to accelerate the delivery of new therapies through AI-based innovative solutions. The company has a highly scalable Hit-to-Candidate platform that enables the designing and scoring of synthetically accessible drug candidates. Evariste has a set of advanced internal projects around synthetic lethality, immuno-oncology and DNA damage response. In addition, Evariste collaborates with other research organisations using the platform to advance their drug discovery programs.
"Adopting CDD Vault is a great step forward for Evariste," said Anna Hercot, CEO of the company. "Our research operations will now be streamlined, allowing us to focus on delivering the most innovative and impactful solutions on our projects and to our partners. The secure and efficient data management CDD Vault provides will enhance our ability to collaborate with partners, further driving our success."
Evariste will now be able to securely store, organise, and share its research data with partners, streamlining the collaboration process and providing faster access to critical information. CDD Vault's advanced search and reporting tools, collaboration workflows, and customisable security settings will aid in effective data management and support the company's focus on delivering cutting-edge research and development. CDD Vault, used by top companies in pharmaceutical, biotech, and chemical industries, provides research organisations with a comprehensive solution to manage their data. Its cloud-based platform meets the needs of organisations of all sizes, making it a fitting partner for Evariste.
"We're delighted to support Evariste, a leader in the AI-drug discovery field, by providing CDD Vault. We are impressed with the velocity of their rapidly advancing R&D programs," stated Dr Barry Bunin, CEO of Collaborative Drug Discovery, Inc. "We are confident that the adoption of CDD Vault will enable them to improve their data management processes and drive innovation, as it does daily for customers around the world."
About Evariste
Evariste is building the next generation of precision medicines using mathematical modelling and machine learning to identify novel targets and generate new small molecule candidates.
CDD's (www.collaborativedrug.com) flagship product, "CDD Vault®", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.
A complete list of more than 60 publications and patents from CDD can be found online on our resources page at https://www.collaborativedrug.com/publications-and-resources/.
Media Contact: Barry Bunin, Ph.D., Collaborative Drug Discovery, marketing@collaborativedrug.com.